

BOVIN et al
 Appl. No. 10/593,829
 May 20, 2010

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-167 (cancelled).

168 (previously presented). A method of incorporating a synthetic molecule construct of the structure F-S₁-S₂-L into the lipid bi-layer of a cell or a multi-cellular structure including the step:

of contacting a suspension of the cell or multi-cellular structure with the synthetic molecule construct for a time and at a temperature sufficient to allow incorporation where:

F is a mono-, di-, tri- or oligo- saccharide;


S₁ is 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, or 5-aminopentyl;

S₂ is -CO(CH₂)₂CO-, -CO(CH₂)₃CO-,

-CO(CH₂)₄CO- or -CO(CH₂)₅CO-; and

L is a diacyl- or dialkyl- glycerophospholipid.

169 (previously presented). The method according to claim 168 where the construct includes the substructure:



BOVIN et al
Appl. No. 10/593,829
May 20, 2010

where:

$n = 3$ to 5 and M is H .

170 (previously presented). The method according to claim 168 where the cell or multi-cellular structure is of human or murine origin.

171 (previously presented). The method according to claim 168 where the concentration of the construct in the suspension is in the range 0.1 to 10 mg/mL.

172 (previously presented). The method according to 168 where the suspension of the cell or multi-cellular structure is contacted with the construct at a temperature in the range 2 to 37 °C.

173 (previously presented). The method according to claim 172 where the suspension of the cell or multi-cellular structure is contacted with the construct at a temperature in the range 2 to 25 °C.

174 (previously presented). The method according claim 173 where the suspension of the cell or multi-cellular structure is contacted with the construct at a temperature in the range 2 to 4 °C.

175 (previously presented). The method according to claim 168 where F is selected from the group consisting of $\text{GalNAc}\alpha 1-3(\text{Fuc}\alpha 1-2)\text{Gal}\beta$; $\text{Gal}\alpha 1-3\text{Gal}\beta$; $\text{Gal}\beta$;

BOVIN et al
Appl. No. 10/593,829
May 20, 2010

Gal α 1-3(Fuc α 1-2)Gal β ; NeuAc α 2-3Gal β ; NeuAc α 2-6Gal β ; Fuc α 1-2Gal β ; Gal β 1-4GlcNAc β 1-6(Gal β 1-4GlcNAc β 1-3)Gal β ; Fuc α 1-2Gal β 1-4GlcNAc β 1-6(Fuc α 1-2Gal β 1-4GlcNAc β 1-3)Gal β ; Fuc α 1-2Gal β 1-4GlcNAc β 1-6(NeuAc α 2-3Gal β 1-4GlcNAc β 1-3)Gal β ; NeuAc α 2-3Gal β 1-4GlcNAc β 1-6(NeuAc α 2-3Gal β 1-4GlcNAc β 1-3)Gal β ; Gal α 1-4Gal β 1-4Glc; GalNAc β 1-3Gal α 1-4Gal β 1-4Glc; GalNAc α 1-3GalNAc β 1-3Gal α 1-4Gal β 1-4Glc; and GalNAc β 1-3GalNAc β 1-3Gal α 1-4Gal β 1-4Glc.



176 (previously presented). The method according to claim 175 where F is selected from the group consisting of GalNAc α 1-3(Fuc α 1-2)Gal β and Gal α 1-3(Fuc α 1-2)Gal β .

177 (previously presented). The method according to claim 168 where S₁ is 3-aminopropyl.

178 (previously presented). The method according to claim 168 where L is selected from the group consisting of: 1,2-O-dioleoyl-sn-glycero-3-phosphatidylethanolamine (DOPE) and 1,2-O-distearyl-sn-glycero-3-phosphatidylethanolamine (DSPE).

179 (currently amended). The method according to claim 168 where the construct is:


BOVIN et al
 Appl. No. 10/593,829
 May 20, 2010



designated A_{tri}-sp-Ad-DOPE (I).

180 (currently amended). The method according to claim 168 where the construct is:



BOVIN et al
 Appl. No. 10/593,829
 May 20, 2010



designated A_{tri}-sp-Ad-DSPE (III).

181 (currently amended). The method according to claim 168 where the construct is:


BOVIN et al
Appl. No. 10/593,829
May 20, 2010



designated B_{tri}-sp-Ad-DOPE (VI).


182 (currently amended). The method according to claim 168 where the construct is:

BOVIN et al
 Appl. No. 10/593,829
 May 20, 2010




designated H_{tri} -sp-Ad-DOPE (VII).

183 (currently amended). The method according to claim 168 where the construct is:




BOVIN et al
Appl. No. 10/593,829
May 20, 2010



designated H_{di}-sp-Ad-DOPE (VIII).



184 (previously presented). The method according to claim 168 where the construct is:



designated Gal β -sp-Ad-DOPE (IX).

185 (currently amended). The method according to claim 168 where the construct is:


BOVIN et al
Appl. No. 10/593,829
May 20, 2010



designated Fuc α 1-2Gal β 1-3GlcNAc β 1-3Gal β 1-4GlcNAc-sp-Ad-DOPE (XII).

186 (previously presented).
construct is:

The method according to claim 168 where the



BOVIN et al
Appl. No. 10/593,829
May 20, 2010

designated $\text{Fuca}1\text{-}2\text{Gal}\beta 1\text{-}3(\text{Fuca}1\text{-}4)\text{GlcNAc-sp-Ad-DOPE (XIII)}$.

187 (previously presented). The method according to claim 168 where the cell or multi-cellular structure is a red blood cell.

188-189 (cancelled).